{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:47:17Z","timestamp":1780080437549,"version":"3.54.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clgc.2022.07.011","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T22:45:44Z","timestamp":1659048344000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Natural History of Patients with Prostate MRI Likert 1-3 and Development of RosCaP: a Multivariate Risk Score for Clinically Significant Cancer"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-5380","authenticated-orcid":false,"given":"Luca","family":"Orecchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-608X","authenticated-orcid":false,"given":"Simona","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Grounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-6212","authenticated-orcid":false,"given":"Ibifuro","family":"Dokubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-6769","authenticated-orcid":false,"given":"Claudia Fede","family":"Spicchiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiful","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0001","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric Magnetic Resonance Imaging in the detection of clinically significant Prostate Cancer in the Prostate Imaging reporting and data system era: a systematic review and meta-analysis","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.011_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate Magnetic Resonance Imaging, with or without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.07.011_bib0003","unstructured":"Mottet N, Cornford P, Van Den Bergh RC, et\u00a0al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Edn. presented at the EAU Annual Congress Amsterdam 2022."},{"key":"10.1016\/j.clgc.2022.07.011_bib0004","unstructured":"NICE guideline [NG131] - prostate cancer: diagnosis and management. Published online May 9, 2019. https:\/\/www.nice.org.uk\/guidance\/ng131 [Last accessed on 13th February 2022]"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.011_bib0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.crad.2019.05.019","article-title":"PI-RADS version 2.1: one small step for prostate MRI","volume":"74","author":"Barrett","year":"2019","journal-title":"Clin Radiol"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate Imaging Reporting and Data System 3 Category cases at Multiparametric Magnetic Resonance for Prostate Cancer: a systematic review and meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2022.07.011_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejrad.2017.08.017","article-title":"Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection","volume":"95","author":"Hansen","year":"2017","journal-title":"Eur J Radiol"},{"issue":"1118","key":"10.1016\/j.clgc.2022.07.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20191050","article-title":"Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: a systematic review and meta-analysis","volume":"94","author":"Wadera","year":"2021","journal-title":"BJR"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00345-019-02707-9","article-title":"Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions","volume":"38","author":"Schoots","year":"2020","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.011_bib0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","article-title":"Prediction of high-grade prostate cancer following multiparametric Magnetic Resonance Imaging: improving the rotterdam European randomized study of screening for prostate cancer risk calculators","volume":"75","author":"Alberts","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.011_bib0012","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.eururo.2017.03.039","article-title":"Combined clinical parameters and multiparametric Magnetic Resonance Imaging for advanced risk modeling of prostate cancer\u2014patient-tailored risk stratification can reduce unnecessary biopsies","volume":"72","author":"Radtke","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.011_bib0013","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bju.13814","article-title":"A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy","volume":"120","author":"van Leeuwen","year":"2017","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.011_bib0014","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","article-title":"A Magnetic Resonance Imaging\u2013based prediction model for prostate biopsy risk stratification","volume":"4","author":"Mehralivand","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2022.07.011_bib0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/JU.0000000000000622","article-title":"External validation and comparison of Prostate Cancer risk calculators incorporating multiparametric Magnetic Resonance Imaging for prediction of clinically significant Prostate Cancer","volume":"203","author":"Saba","year":"2020","journal-title":"J Urol."},{"issue":"11","key":"10.1016\/j.clgc.2022.07.011_bib0016","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1007\/s00345-021-03770-x","article-title":"External validation of two MRI-based risk calculators in prostate cancer diagnosis","volume":"39","author":"Petersmann","year":"2021","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.011_bib0017","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bju.13619","article-title":"The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting","volume":"119","author":"Hansen","year":"2017","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.011_bib0018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bju.14361","article-title":"National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting","volume":"122","author":"Brizmohun Appayya","year":"2018","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.011_bib0019","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1148\/radiol.2021204112","article-title":"Avoiding unnecessary Biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer","volume":"300","author":"Deniffel","year":"2021","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2019.06.004","article-title":"Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways","volume":"74","author":"Barrett","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.clgc.2022.07.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211372","article-title":"Prostate MRI quality: clinical impact of the PI-QUAL score in prostate cancer diagnostic work-up","author":"Karanasios","year":"2022","journal-title":"BJR"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0022","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bju.15285","article-title":"Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting","volume":"127","author":"Barrett","year":"2021","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.clgc.2022.07.011_bib0023","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","article-title":"ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training","volume":"30","author":"de Rooij","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clgc.2022.07.011_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-015-0087-5","article-title":"Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma","volume":"15","author":"Harada","year":"2015","journal-title":"BMC Urol"},{"issue":"1112","key":"10.1016\/j.clgc.2022.07.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200298","article-title":"Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer","volume":"93","author":"Zawaideh","year":"2020","journal-title":"BJR"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2019.08.020","article-title":"Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases","volume":"74","author":"Latifoltojar","year":"2019","journal-title":"Clin Radiol"},{"issue":"1131","key":"10.1016\/j.clgc.2022.07.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210413","article-title":"Optimal biopsy approach for detection of clinically significant prostate cancer","volume":"95","author":"Ippoliti","year":"2022","journal-title":"BJR"},{"issue":"9","key":"10.1016\/j.clgc.2022.07.011_bib0028","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.011_bib0029","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eururo.2018.03.007","article-title":"Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.011_bib0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/bju.14853","article-title":"Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men: mpMRI and follow up to avoid prostate biopsy","volume":"124","author":"Venderink","year":"2019","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.clgc.2022.07.011_bib0031","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.crad.2019.06.013","article-title":"Special issue on prostate imaging","volume":"74","author":"Barrett","year":"2019","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.011_bib0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.14916","article-title":"Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer","volume":"125","author":"Khoo","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.07.011_bib0033","article-title":"Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways","author":"Lophatananon","year":"2021","journal-title":"J Clin Urol"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0034","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bju.15484","article-title":"The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines","volume":"128","author":"Light","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.07.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.01.018","article-title":"The association between age, prostate cancer risk, and higher gleason score in a long-term screening program: results from the G\u00f6teborg-1 prostate cancer screening trial","author":"Godtman","year":"2022","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2022.07.011_bib0036","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cncr.32702","article-title":"Age dependence of modern clinical risk groups for localized prostate cancer\u2014a population-based study","volume":"126","author":"Huynh-Le","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.011_bib0037","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and Magnetic Resonance Imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)","volume":"4","author":"Falagario","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.euo.2018.09.001","article-title":"Prebiopsy Biparametric Magnetic Resonance Imaging combined with prostate-specific antigen density in detecting and ruling out gleason 7\u201310 prostate cancer in biopsy-na\u00efve men","volume":"2","author":"Boesen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2022.07.011_bib0039","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort","author":"Clements","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2022.07.011_bib0040","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cancers13092154","article-title":"Germline genetics of prostate cancer: prevalence of risk variants and clinical implications for disease management","volume":"13","author":"Doan","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.011_bib0041","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13685538.2020.1786047","article-title":"Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era?","volume":"24","author":"Tan","year":"2021","journal-title":"Aging Male"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.011_bib0042","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bju.15119","article-title":"A reflection on an adapted approach from face-to-face to telephone consultations in our Urology Outpatient Department during the COVID-19 pandemic - a pathway for change to future practice? Changing Urology practice due to COVID-19","volume":"126","author":"Patel","year":"2020","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.011_bib0043","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MOU.0000000000000957","article-title":"The impact of COVID-19 on urology office visits and adoption of telemedicine services","volume":"32","author":"Butaney","year":"2022","journal-title":"Curr Opin Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:22Z","timestamp":1761565042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1558767322001665"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History of Patients with Prostate MRI Likert 1-3 and Development of RosCaP: a Multivariate Risk Score for Clinically Significant Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}